問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

China Medical University Hospital

List

1712Cases

2013-05-28 - 2016-09-21

Phase III

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Blisibimod Administration in Subjects with Systemic Lupus Erythematosus

  • Condition/Disease

    Systemic Lupus Erythematosus

  • Test Drug

    Blisibimod

Participate Sites
5Sites

Terminated4Sites

Study ended1Sites

黃春明
China Medical University Hospital

2013-07-01 - 2017-05-26

Phase II/III

A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Evaluate the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy

  • Condition/Disease

    IgA Nephropathy

  • Test Drug

    Blisibimod

Participate Sites
6Sites

Terminated6Sites

2013-08-22 - 2015-06-30

Phase III

A randomized, double-blind, double-dummy, parallel group, international multicenter study assessing the efficacy and safety of a netupitant-palonosetron Fixed Dose Combination (FDC) compared to an extemporary combination of granisetron and aprepitant on the prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with cancer.

  • Condition/Disease

    nausea and vomiting

  • Test Drug

    netupitant-palonosetron Fixed Dose Combination (FDC)

Participate Sites
7Sites

Terminated7Sites

葉士芃
China Medical University Hospital

Division of Hematology & Oncology

2018-11-01 - 2021-12-31

Phase III

A Randomized, Controlled, Double-blind Continuation Study Comparing the Long-term Safety and Efficacy of Orelvo (voclosporin) (23.7 mg Twice Daily) with Placebo in Subjects with Lupus Nephritis

  • Condition/Disease

    Lupus Nephritis

  • Test Drug

    Orelvo (voclosporin)

Participate Sites
4Sites

Terminated2Sites

藍忠亮
China Medical University Hospital-Taipei

未分科

藍忠亮
China Medical University Hospital

Division of Rheumatology

2014-07-01 - 2020-12-31

Phase III

A Multicentre, Randomized, Open-Label, Phase III Clinical Trial Of Gemcitabine And Carboplatin Followed By Epstein-Barr Virus-Specific Autologous Cytotoxic T Lymphocytes Versus Gemcitabine And Carboplatin As First Line Treatment For Advanced Nasopharyngeal Carcinoma Patients

  • Condition/Disease

    Advanced Nasopharyngeal Carcinoma

  • Test Drug

    Epstein-Barr virus-specific autologous cytotoxic T lymphocytes

Participate Sites
8Sites

Terminated7Sites

王宏銘
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

謝清昀
China Medical University Hospital-Taipei

未分科

2015-08-01 - 2017-07-31

Phase III

A randomized, double-blind, placebo-controlled confirmatory study of the safety and efficacy of ASP015K in patients with rheumatoid arthritis (RA) who had an inadequate response to DMARDs

  • Condition/Disease

    rheumatoid arthritis (RA) who had an inadequate response to DMARDs

  • Test Drug

    ASP015K

Participate Sites
11Sites

Terminated10Sites

方耀凡
Linkou Chang Gung Medical Foundation

Division of Rheumatology

蔡文展
Kaohsiung Municipal Gangshan Hospital

未分科

2017-04-01 - 2019-07-31

Phase III

A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Orelvo (voclosporin) (23.7 mg Twice Daily) with Placebo in Achieving Renal Response in Subjects with Active Lupus Nephritis

  • Condition/Disease

    Active Lupus Nephritis

  • Test Drug

    Orelvo (voclosporin)

Participate Sites
5Sites

Terminated3Sites

Study ended1Sites

藍忠亮
China Medical University Hospital-Taipei

未分科

藍忠亮
China Medical University Hospital

Division of Rheumatology

2014-10-01 - 2021-04-20

Phase III

Randomized, Double blind, Placebo-controlled Trial of Z-100 plus Radiation Therapy in Patients with Locally Advanced Cervical Cancer — A Phase III trial

  • Condition/Disease

    FIGO stage IIIB cervical cancer

  • Test Drug

    Z-100

Participate Sites
17Sites

Terminated17Sites

2019-03-01 - 2020-12-31

Phase I

Clinical Pharmacology of LT5001 Drug Product in Hemodialysis Patients With Uremic Pruritus to Assess the Safety, Local Tolerance and Pharmacokinetics

  • Condition/Disease

    Hemodialysis Patients With Uremic Pruritu

  • Test Drug

    LT5001 drug product

Participate Sites
1Sites

Terminated1Sites

黃秋錦
China Medical University Hospital

Division of Nephrology

2009-12-01 - 2011-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

1 107 108 109 110 111 172
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB